New GLP-1 RA ‘better than semaglutide’ for weight loss in Lancet study
Ecnoglutide was associated with a 5% or greater reduction in body weight in more than 75% of participants treated.
A high dose of a new once-weekly injected GLP-1 receptor agonist has outdone semaglutide for weight loss in a phase III trial.
Ecnoglutide, developed in China, appeared to reduce body weight by 5% or more in up to 87% of patients during a 48-week, randomised, double-blind trial of 664 people with overweight but not diabetes.
Some 499 patients received one of three different doses of ecnoglutide — 1.2mg, 1.8mg or 2.4mg — and 165 received a placebo.
All patients had a BMI of 28kg/m² or higher, or 24kg/m² or higher with more than one weight-related comorbidity.
